In a country where a single bite of a mosquito can trigger a chain of medical emergencies, the ability to diagnose several infections from one sample is a game changer. India’s population of over 1.4 billion faces a high incidence of vector‑borne illnesses such as dengue, chikungunya and malaria. At the same time, bacterial infections like typhoid keep spreading in crowded urban and rural settings. For frontline health workers, the time and resources required to run separate tests for each disease can delay treatment and strain limited laboratory capacity.
The Indian Council of Medical Research (ICMR) has tackled this challenge by creating a multiplex test that detects dengue, chikungunya and malaria from a single blood sample. The new test can be performed in a fraction of the time it takes for conventional methods, allowing doctors to act quickly and accurately.
At its core, the ICMR test uses a technology called reverse transcription polymerase chain reaction (RT‑PCR). RT‑PCR is already a staple in many diagnostic labs for detecting viral and bacterial nucleic acids. The novelty lies in its multiplex format – the assay is designed to amplify genetic markers for all three diseases simultaneously.
The procedure begins with a simple finger‑prick or venous blood draw. The sample is placed in a cartridge that contains reagents for all three target pathogens. Within about 30 minutes, the RT‑PCR machine reads the signals and reports which infections are present. Because the test targets distinct genetic sequences for each disease, cross‑reactivity is minimal, giving clinicians confidence in the results.
One of the key advantages is the minimal sample volume needed. A single drop of blood can suffice, making it ideal for children and patients who cannot provide large volumes. The cartridge is also sealed, reducing the risk of contamination and the need for sophisticated lab infrastructure.
The test targets three of the most common febrile illnesses in India:
By identifying all three infections at once, the test eliminates the need for separate serology or microscopy, which can be slow and less sensitive in early disease stages.
The most immediate benefit is the reduction in time to treatment. In many rural hospitals, a patient presenting with fever might wait several days for laboratory confirmation. With the multiplex test, results are available in under an hour, enabling doctors to start the appropriate medication right away.
For dengue, early fluid management can prevent the progression to dengue haemorrhagic fever. In chikungunya, identifying the virus early helps set realistic expectations for the recovery period and guides pain management. In malaria, early detection is crucial to prevent severe anemia and cerebral complications.
The test also aids in public health surveillance. When health workers can confirm multiple infections quickly, they can report outbreaks more reliably, allowing authorities to deploy vector control measures or allocate resources to affected areas promptly.
Laboratories in district hospitals and primary health centers often lack the capacity to run multiple separate tests. The multiplex assay requires only a single machine and a small consumable kit, keeping operational costs lower. Because the test uses a closed cartridge system, the risk of cross‑contamination is reduced, which is important for maintaining quality standards.
The simplified workflow also means that less trained staff can operate the machine under supervision. This is a significant advantage in regions where skilled laboratory personnel are scarce.
While the test offers many advantages, there are hurdles to widespread adoption. The RT‑PCR machine, though portable, still requires a stable power supply and temperature control. In some remote villages, intermittent electricity can pose a problem.
The cost of the cartridge is higher than that of a single serology kit. However, when the savings from reduced repeat testing and faster patient turnaround are considered, the overall cost may be justified. Health ministries and public‑private partnerships can explore subsidy models to make the test more affordable.
Looking ahead, ICMR is already working on expanding the panel. Adding tests for bacterial infections like typhoid or viral pathogens such as SARS‑CoV‑2 could make the platform even more valuable. Integrating the assay into a larger electronic health record system would also streamline data collection for epidemiological studies.
For patients, a single test means less discomfort and fewer visits to the clinic. Families no longer need to wait for multiple appointments to confirm the cause of a fever. This is especially important for children, whose tolerance for repeated blood draws is limited.
Doctors gain a reliable diagnostic tool that supports evidence‑based treatment decisions. In an environment where empirical medication is sometimes the default, having concrete laboratory confirmation reduces the risk of incorrect therapy and antimicrobial resistance.
The ICMR multiplex test represents a practical step toward more efficient, accurate, and patient‑friendly diagnostics in India. By combining detection of dengue, chikungunya and malaria into a single, rapid assay, the test aligns laboratory capability with the realities of Indian healthcare delivery. As the technology matures and expands, it could become a cornerstone of fever management across the country.
© 2026 The Blog Scoop. All rights reserved.
Why Nasal Breathing Matters in Exercise Every workout session is driven by oxygen. When the body receives a steady stream of air, muscles can perfor...
Why a 3‑Minute Stretch Can Change Your Posture Every day, millions of Indians reach for their phones. Whether it’s a quick check of WhatsApp, a scro...
Why the buzz around red light therapy? Hair loss is a common concern for many Indians, especially as urban lifestyles and pollution take their toll....